Clinical trial with Remygen[®] is expanded to evaluate prevention of hypoglycaemia

The Swedish Medical Products Agency has approved an amendment to ReGenerate-1 to investigate Remygen[®]'s preventive effects on hypoglycaemia (severely reduced blood sugar level) in individuals with long-term type 1 diabetes.”With this amendment to the study protocol, we can investigate in detail both Remygen's stimulating effects on the insulin-producing cells as well as its effect as a hypoglycemia-preventing drug, alone and together with Alprazolam”, says Per-Ola Carlsson, Professor at Uppsala University and Akademiska sjukhuset, Sponsor of the trial. The results of the initial safety